Inhibrx, Inc. (NASDAQ:INBX – Get Rating) CEO Mark Lappe sold 26,000 shares of the company’s shares in a transaction on Monday, December 19. The shares were sold at an average price of $25.56 for a total transaction of $664,560.00. Following the sale, the Chief Executive Officer now owns 2,512,252 shares of the Company, valued at approximately $64,213,161.12. The sale was disclosed in a legal filing with the SEC available at this link.
Mark Lappe also recently made the following trades:
- On Monday October 17th, Mark Lappe sold 26,000 shares of Inhibrx. The stock sold at an average price of $29.59 for a total transaction of $769,340.00.
Inhibrx stock performance
NASDAQ INBX shares rose $1.64 on Tuesday afternoon to hit $27.25. The company’s shares had a trading volume of 633,399 shares compared to an average volume of 488,124. The stock has a market cap of $1.19 billion, a P/E of -7.95 and a beta of 3.08. The company has a leverage ratio of 4.16, a current ratio of 6.05 and a quick ratio of 6.05. The company has a 50-day moving average price of $30.15 and a 200-day moving average price of $21.63. Inhibrx, Inc. has a 12-month low of $7.67 and a 12-month high of $45.99.
Institutional inflows and outflows
Hedge funds and other institutional investors have recently bought and sold shares in the company. Platinum Investment Management Ltd. increased its holding in Inhibrx shares by 84.2% during the second quarter. Platinum Investment Management Ltd. now owns 160,099 shares of the company’s stock valued at $1,817,000 after purchasing an additional 73,170 shares last quarter. Sio Capital Management LLC increased its stake in Inhibrx by 193.9% in the second quarter. Sio Capital Management LLC now owns 365,210 shares of the company’s stock valued at $4,145,000 after purchasing an additional 240,960 shares last quarter. Bioimpact Capital LLC acquired a new position in shares of Inhibrx valued at approximately $11,615,000 during the second quarter. Opaleye Management Inc. acquired a new interest in Inhibrx stock valued at approximately $6,697,000 during the second quarter. Finally, the Swiss National Bank increased its holding in Inhibrx shares by 138.2% during the second quarter. The Swiss National Bank now owns 53,600 shares of the company, valued at $608,000, after purchasing an additional 31,100 shares during the period. Hedge funds and other institutional investors own 67.27% of the company’s shares.
Analysts set new price targets
A number of equity analysts have issued reports on the company. Credit Suisse Group lowered its price target on Inhibrx to $46.00 from $48.00 and gave the company a rating of “outperform” in a research note on Tuesday, November 8th. Evercore ISI increased its target price on Inhibrx to $60.00 from $54.00 and gave the stock a “Outperform” rating in a report on Wednesday, October 5. Finally, on Wednesday, October 5, JMP Securities issued a research report that issued a “buy” rating and a price target of $40.00 on shares of Inhibrx.
Inhibrx company profile
Inhibrx, Inc, a clinical-stage biotechnology company, is focused on developing a pipeline of novel biological therapeutic candidates. The Company’s therapeutic candidates include INBRX-109, a tetravalent death receptor 5 agonist in Phase 2 clinical trials for the treatment of cancers such as chondrosarcoma, mesothelioma and pancreatic adenocarcinoma; INBRX-105, a tetravalent programmed death ligand 1 conditional agonist and a 4-1BB conditional agonist in Phase 1 clinical trials for the treatment of patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1-antitrypsin (AAT)-Fc fusion protein therapeutic candidate that is in Phase 1 clinical trials for use in treating patients with AAT deficiency.
This instant news alert was generated by MarketBeat’s narrative science technology and financial data to provide readers with the fastest, most accurate reporting. This story was reviewed by the MarketBeat editorial team prior to publication. Please send questions or comments about this story to [email protected].
Before you consider Inhibrx, here’s what you should hear.
MarketBeat tracks Wall Street’s best-in-class, top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now, before the broader market takes hold… and Inhibrx didn’t make the list.
While Inhibrx currently has a buy rating among analysts, top analysts believe these five stocks are better buys.
Check out the five stocks here